Aldeyra Therapeutics (ALDX) Announces Proposed $125 Million Public Offering of Common Stock

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced that it intends to offer and sell, subject to market and other conditions, $125 million of shares of its common stock in an underwritten public offering. Aldeyra also expects to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of common stock sold in the offering, at the public offering price, less the underwriting discounts and commissions. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the offering are to be sold by Aldeyra, with net proceeds to be used for the preparation of a potential New Drug Application submission for Aldeyra’s lead compound, reproxalap; the preparations for the commercial launch of reproxalap and the subsequent commercialization of reproxalap, if approved; early stage pipeline development programs, as well as for working capital and other general corporate purposes.

Jefferies and SVB Leerink are acting as joint book-running managers for the offering.

You May Also Be Interested In

• Definium Therapeutics plans $500M public share offering
• AbbVie agrees to acquire Apogee Therapeutics for $10.9 billion
• Ruanyun Edai Technology (RYET) files for 20M share offering by selling stockholders